CleveMed sues ResMed over patent infringement
Ohio-based Cleveland Medical Devices (CleveMed) has accused ResMed of infringing patents through the sale of devices and software for the testing and treatment of sleep-disordered breathing or apnea.
Glycosyn sues Abbott over infant formula method
Biotech company Glycosyn has sued Abbott Laboratories for allegedly infringing its patented method for manufacturing a key ingredient in infant formula milk, found in three of Abbott’s infant formula products under the Similac brand.
Zydus challenges ruling in Takeda antitrust dispute
Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
BMS petitions SCOTUS to revive $1.2bn win
BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
WTO releases draft COVID-19 response after ‘very difficult process’
The World Trade Organization has issued draft texts relating to its IP response to the COVID-19.
Takeda unit urges Fed Circ to revive antibody patent
Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent.
Teva settles patent dispute with Aurobindo
Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Novartis, Dana-Farber seek to bar generic leukaemia drug
Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.
Senators urge USPTO to curb ‘patent thicket’ abuse
A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Pfizer sues MSN Labs over Xeljanz generic
Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.
